Cargando…

Boosting with Multiple Doses of mRNA Vaccine after Priming with Two Doses of Protein Subunit Vaccine MVC-COV1901 Elicited Robust Humoral and Cellular Immune Responses against Emerging SARS-CoV-2 Variants

Confronted with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants, such as Delta and Omicron, with high infectivity and immune evasion capacity, vaccination remains the most effective tool to prevent infection and severe illness. However, heterologous vaccination of mRNA vaccines...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chiu, Chun-Hsiang, Chang, Yu-Hsiu, Tao, Chi-Wei, Chang, Feng-Yee, Chiu, Kuo-Chou, Chang, Tien-Wei, Yen, Li-Chen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9602831/ https://www.ncbi.nlm.nih.gov/pubmed/36005765 http://dx.doi.org/10.1128/spectrum.00609-22

Ejemplares similares

Safety and immunogenicity of MVC-COV1901 vaccine in older adults: Phase 2 randomized dose-comparison trial
por: Waits, Alexander, et al.
Publicado: (2022)

Safety and immunogenicity of SARS-CoV-2 vaccine MVC-COV1901 in Taiwanese adolescents: a randomized phase 2 trial
por: Liu, Luke Tzu-Chi, et al.
Publicado: (2022)

Safety and Immunogenicity of a Heterologous Booster of Protein Subunit Vaccine MVC-COV1901 after Two Doses of Adenoviral Vector Vaccine AZD1222
por: Cheng, Shu-Hsing, et al.
Publicado: (2022)

A Retrospective Study of the Safety and Immunogenicity of MVC-COV1901 Vaccine for People Living with HIV
por: Cheng, Shu-Hsing, et al.
Publicado: (2022)

Durability and Immunogenicity of Neutralizing Antibodies Response Against Omicron Variants After Three Doses of Subunit SARS-CoV-2 Vaccine MVC-COV1901: An Extension to an Open-Label, Dose-Escalation Phase 1 Study
por: Hsieh, Szu-Min, et al.
Publicado: (2022)

A randomized controlled trial of heterologous ChAdOx1 nCoV-19 and recombinant subunit vaccine MVC-COV1901 against COVID-19
por: Chen, Chih-Jung, et al.
Publicado: (2022)

Protection of hamsters challenged with SARS-CoV-2 after two doses of MVC-COV1901 vaccine followed by a single intranasal booster with nanoemulsion adjuvanted S-2P vaccine
por: Lin, Yi-Jiun, et al.
Publicado: (2022)

An Immunobridging Study to Evaluate the Neutralizing Antibody Titer in Adults Immunized with Two Doses of Either ChAdOx1-nCov-19 (AstraZeneca) or MVC-COV1901
por: Estrada, Josue Antonio, et al.
Publicado: (2022)

Safety and immunogenicity of a Recombinant Stabilized Prefusion SARS-CoV-2 Spike Protein Vaccine (MVC—COV1901) Adjuvanted with CpG 1018 and Aluminum Hydroxide in healthy adults: A Phase 1, dose-escalation study
por: Hsieh, Szu-Min, et al.
Publicado: (2021)

Safety and immunogenicity of homologous versus heterologous booster dose with AZD1222, mRNA-1273, or MVC-COV1901 SARS-CoV-2 vaccines in adults: An observer-blinded, multi-center, phase 2 randomized trial
por: Estephan, Lila, et al.
Publicado: (2023)

Immunogenicity and safety of heterologous mRNA-1273/MVC-COV1901 vaccination versus homologous mRNA1273 vaccination: A randomized, double-blind controlled study
por: Huang, Szu-Ting, et al.
Publicado: (2023)

Broad humoral and cellular immunity elicited by one-dose mRNA vaccination 18 months after SARS-CoV-2 infection
por: Kang, Chang Kyung, et al.
Publicado: (2022)

Humoral Responses Elicited after a Fifth Dose of SARS-CoV-2 mRNA Bivalent Vaccine
por: Tauzin, Alexandra, et al.
Publicado: (2023)

Heterologous Prime-Boost Vaccination with Commercial FMD Vaccines Elicits a Broader Immune Response than Homologous Prime-Boost Vaccination in Pigs
por: Kim, Jaejo, et al.
Publicado: (2023)

Humoral, Cellular and Cytokine Immune Responses Against SARS-CoV-2 Variants in COVID-19 Convalescent and Confirmed Patients With Different Disease Severities
por: Chiu, Chun-Hsiang, et al.
Publicado: (2022)

A boost with SARS-CoV-2 BNT162b2 mRNA vaccine elicits strong humoral responses independently of the interval between the first two doses
por: Tauzin, Alexandra, et al.
Publicado: (2022)

Neutralization of SARS-CoV-2 Omicron BA.1, BA.4, and BA.5 by primary ChAdOx1 nCoV-19, mRNA-1273, MVC-COV1901 and booster mRNA-1273 vaccination
por: Liu, Yuag-Meng, et al.
Publicado: (2022)

Antibody response elicited by a third boost dose of inactivated SARS-CoV-2 vaccine can neutralize SARS-CoV-2 variants of concern
por: Yue, Lei, et al.
Publicado: (2021)

Durable CD8 T Cell Memory against SARS-CoV-2 by Prime/Boost and Multi-Dose Vaccination: Considerations on Inter-Dose Time Intervals
por: Natalini, Ambra, et al.
Publicado: (2022)

Boosting maternal and neonatal anti–SARS-CoV-2 humoral immunity using a third mRNA vaccine dose
por: Cahen-Peretz, Adva, et al.
Publicado: (2023)

The Effects of Heterologous Immunization with Prime-Boost COVID-19 Vaccination against SARS-CoV-2
por: Ho, Tzu-Chuan, et al.
Publicado: (2021)

Durability of SARS-CoV-2 specific immune response following different primary prime-boost vaccine platforms and subsequent humoral response to booster dose among liver transplant recipients
por: Sriphoosanaphan, Supachaya, et al.
Publicado: (2022)

Humoral Response to the Third Dose of Sars-Cov-2 Vaccine in Kidney Transplant Recipients
por: Grupper, Ayelet, et al.
Publicado: (2022)

Subunit vaccines with a saponin-based adjuvant boost humoral and cellular immunity to MERS coronavirus
por: Chang, Chi-Chieh, et al.
Publicado: (2023)

A three-dose inactivated SARS-CoV-2 vaccine is sufficient to elicit humoral immune responses in people living with HIV-1
por: Yu, Haisheng, et al.
Publicado: (2023)

Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines
por: Cao, Yunlong, et al.
Publicado: (2021)

Boosting maternal and neonatal humoral immunity following SARS-CoV-2 infection using a single messenger RNA vaccine dose
por: Nevo, Lea, et al.
Publicado: (2022)

Intensified antibody response elicited by boost suggests immune memory in individuals administered two doses of SARS-CoV-2 inactivated vaccine
por: Liao, Yun, et al.
Publicado: (2021)

Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan
por: Hsieh, Szu-Min, et al.
Publicado: (2021)

Immunogenicity of Low-Dose Prime-Boost Vaccination of mRNA Vaccine CV07050101 in Non-Human Primates
por: van Doremalen, Neeltje, et al.
Publicado: (2021)

Immunogenicity of low dose prime-boost vaccination of mRNA vaccine CV07050101 in non-human primates
por: van Doremalen, Neeltje, et al.
Publicado: (2021)

Adaptive immune responses and cytokine immune profiles in humans following prime and boost vaccination with the SARS-CoV-2 CoronaVac vaccine
por: Wang, Chan, et al.
Publicado: (2022)

Prime and Boost Vaccination Elicit a Distinct Innate Myeloid Cell Immune Response
por: Palgen, Jean-Louis, et al.
Publicado: (2018)

Previous SARS‐CoV‐2 infection or a third dose of vaccine elicited cross‐variant neutralising antibodies in vaccinated solid‐organ transplant recipients
por: Chang, Chih‐Chao, et al.
Publicado: (2022)

Prime-boost, double-dose influenza vaccine immunity in COPD: a pilot observational study
por: Anderson, Gary P., et al.
Publicado: (2023)

Potent cellular and humoral immunity against HIV-1 elicited in mice by a DNA-prime/MVA-boost vaccine regimen intended for human use
por: Wahren, Britta, et al.
Publicado: (2006)

Humoral immunity to SARS-CoV-2 elicited by combination COVID-19 vaccination regimens
por: Wang, Zijun, et al.
Publicado: (2022)

Dynamics of the Humoral Immune Response to a Prime-Boost Ebola Vaccine: Quantification and Sources of Variation
por: Pasin, Chloé, et al.
Publicado: (2019)

Immunogenicity of prime-boost protein subunit vaccine strategies against SARS-CoV-2 in mice and macaques
por: Tan, Hyon-Xhi, et al.
Publicado: (2021)

SARS-CoV-2 S1 Subunit Booster Vaccination Elicits Robust Humoral Immune Responses in Aged Mice
por: Kim, Eun, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_kfgpdhiq1tdir57888om9jqmh2